NCCN upgraded support to category 2A for BCG-unresponsive high-grade papillary Ta/T1 without CIS, while maintaining category ...
Everyday Health on MSN
8 treatments for metastatic bladder cancer pain
Bladder cancer can cause pain when it spreads to different areas of the body. From NSAIDs to nerve blocks, here are the ...
Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced that China's National Medical Products ...
The MarketWatch News Department was not involved in the creation of this content.-- Nadofaragene firadenovec-vncg received an NCCN Category 2A recommendation for patients with pap ...
As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...
Ferring Pharmaceuticals announces that nadofaragene firadenovec-vncg (ADSTILADRIN ® ) has been upgraded to a National Comprehensive Cancer Network ® (NCCN ® ) Category 2A recommended option for the ...
Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well ...
The combination of nogapendekin alfa inbakicept-pmln (Anktiva) and Bacillus Calmette-Guérin was added to the NCCN clinical ...
NCCN now includes Anktiva plus BCG for BCG-unresponsive papillary-only NMIBC, acknowledging an unmet need in patients without CIS who have limited post-BCG options. Radical cystectomy remains ...
Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well ...
A phase 2 trial evaluated the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in patients with urothelial non-muscle invasive bladder cancer.
The phase 2, single-arm INDIBLADE trial assessed induction ipilimumab plus nivolumab followed by CRT in patients with MIBC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results